Successful Treatment With Infliximab in a Patient With Diffuse Subretinal Fibrosis Syndrome

An ENU-Induced Mutation in theMertkGene (Mertknmf12) Leads to a Slow Form of Retinal Degeneration

“…26 Similarly, in many other types of retinal disease, increased levels of TNF are associated with increased retinal degeneration. Because of this, TNF inhibitory antibodies (infliximab, etanercept) have been developed and are being used in trials to treat human diseases such as agerelated macular degeneration, 27 Eales disease, 28 neurosarcoidosis, 29 various forms of ocular inflammation, 30 diffuse subretinal fibrosis syndrome, 31 and glaucoma. 32 As has been noted 33 and as our present study underscores, there are instances in which TNF plays a poorly understood protective role in retinal degeneration.…”

Anti-Tumor Necrosis Factor-α Agents in Noninfectious Uveitis

“…However, this patient died of disseminated tuberculosis (TB) after treatment [74]. Infliximab was also beneficial in patients with idiopathic refractory uveitis [51,60,75,76] and diffuse subretinal fibrosis syndrome [77]. Etanercept has no significant efficacy over placebo in preventing relapses of idiopathic uveitis [15].…”

Biologics in the treatment of uveitis

“…Posterior uveitis related to Behcet's disease appears to respond rapidly to infliximab infusions (less than 7 days to 3 weeks), whereas non-Behcet's posterior uveitis responds more variably (6 days to 2 months) [2]. Recent reports [14,15,17,20] of infliximab therapy in posterior and intermediate uveitis concentrate on patients with Behcet's disease, but case series and case reports have also included patients with idiopathic uveitis, sarcoidosis, birdshot chorioretinopathy, multifocal choroiditis, Vogt-Koyanagi-Harada disease and diffuse subretinal fibrosis syndrome [2, 8,10,16,18,19,22]. The open-label cohort study by Tugal-Tutkun et al [17] confirmed successful reduction in ocular inflammation and frequency of attacks in 13 patients with Behcet's uveitis treated with infliximab.…”

“…Infliximab has been shown in a large number of recently published reports [2, 8,[10][11][12][13][14][15][16][17][18][19][20][21][22] to be effective in the treatment of both anterior and posterior uveitis. Infliximab is delivered by intravenous infusion, usually at a dose of 3-10 mg/kg per infusion, but doses of 10-20 mg/kg have been used with reported success and few side effects in a group of 17 children with chronic uveitis [19].…”